XML 17 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 14, 2025
Jun. 30, 2024
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-39717    
Entity Registrant Name LIXTE BIOTECHNOLOGY HOLDINGS, INC.    
Entity Central Index Key 0001335105    
Entity Tax Identification Number 20-2903526    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 680 East Colorado Boulevard    
Entity Address, Address Line Two Suite 180    
Entity Address, City or Town Pasadena    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91101    
City Area Code 631    
Local Phone Number 830-7092    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 5,195,000
Entity Common Stock, Shares Outstanding   2,684,074  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 572    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Lixte Biotechnology Holdings, Inc. and subsidiary (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders’ equity and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name Weinberg & Company, P.A    
Auditor Location Los Angeles, California    
Common Stock, par value $0.0001 per share      
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol LIXT    
Security Exchange Name NASDAQ    
Warrants to Purchase Common Stock, par value $0.0001 per share      
Title of 12(b) Security Warrants to Purchase Common Stock, par value $0.0001 per share    
Trading Symbol LIXTW    
Security Exchange Name NASDAQ